Last updated August 24, 2026
Key finding
The two hour post prandial blood glucose (2HPG) levels were significantly lower in the metformin group than the insulin group (p= 0.004).
This study compared metformin and insulin monotherapy for managing diabetes during pregnancy, finding that metformin significantly lowered two-hour post prandial blood glucose levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared metformin and insulin monotherapy for managing diabetes during pregnancy, finding that metformin significantly lowered two-hour post prandial blood glucose levels.
These findings are significant for managing diabetes in pregnant women, as controlling blood sugar levels is crucial for the health of both the mother and the baby. The effective use of metformin could provide a safer and more convenient option for diabetes management during pregnancy.
The study's sample size may limit the generalizability of the findings. Potential confounding factors were not controlled for, which could affect outcomes. The study did not assess long-term effects of treatment on maternal and fetal health.
Published in
Publication details and source links for this paper.
Titus B, Samuel AO, Kenneth KA, et al. Metformin Monotherapy versus Insulin Monotherapy in Diabetes Management during Pregnancy: A Randomized Controlled Trial. PLOS ONE. 2015;10(5):e0125712. doi:10.1371/journal.pone.0125712
Metformin significantly reduced two-hour post prandial blood glucose levels by 1.21 mmol/L (p=0.004) compared to insulin.
Fasting blood glucose levels were similar in both treatment groups (p=0.928).
One-hour post prandial blood glucose levels showed no significant difference between the two groups (p=0.078).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin therapy, Metformin and Fasting blood sugar (FBS), Glucose iAUC (OGTT).
This study contributes evidence to
Primary intervention
Insulin therapy
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
4
Evidence pairs
907
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Insulin therapy → Fasting blood sugar (FBS)
Insulin therapy → Fasting blood sugar (FBS)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Postprandial and OGTT Glucose, Insulin Therapies and Postprandial and OGTT Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
Jump to pre-filtered views in Evidence Explorer.
6 results
4 results
6 results
4 results
6 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies may improve fasting glucose.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Strong | EvidenceScore™ 78.8 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Insulin Therapies may improve fasting glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Metformin Therapies may improve postprandial and ogtt glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 82.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Insulin Therapies may improve postprandial and ogtt glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
